NCT04179032View on ClinicalTrials.gov

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 28, 2019

Primary Completion Date

January 16, 2023

Study Completion Date

April 26, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
COMBINATION_PRODUCT

Belimumab

Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.

Trial Locations (11)

2000

GSK Investigational Site, Rosario

13353

GSK Investigational Site, Berlin

28034

GSK Investigational Site, Madrid

45229

GSK Investigational Site, Cincinnati

46026

GSK Investigational Site, Valencia

53757

GSK Investigational Site, Saint Augustin

78213

GSK Investigational Site, San Luis Potosí City

890-8520

GSK Investigational Site, Kagoshima

216-8511

GSK Investigational Site, Kanagawa

3015 GJ

GSK Investigational Site, Rotterdam

08950

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04179032 - Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter